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Abstract  
Importance.  Although national guidelines recommend the use of intravenous insulin to control 
hyperglycaemia in acute coronary syndromes, there is limited evidence of survival benefit from this 
treatment.   
Objective To determine whether the use of intravenous insulin infusions to control admission 
hyperglycaemia (>=200 mg/dl.) is associated, in contemporary clinical practice, with survival benefit 
when compared to patients receiving routine care. 
Design.  We used matched propensity analysis to examine observational data from a large national 
database for first admissions with acute coronary syndrome. We matched 5974 patients having 
intravenous infusions with the same number having routine care from a total cohort of 23506 patients 
with an admission glucose >=200 mg/dl who had either type 2 diabetes or were not known to have 
diabetes at admission to hospital.  We separately examined the effect of insulin infusions for ST 
elevation and non-ST segment elevation infarctions, and for type 2 diabetes and those without known 
diabetes.  
Setting   Acute admissions to 220 hospitals in England and Wales between January 2008 and March 
2012 who had a final diagnosis of acute coronary syndrome. 
Outcome   Survival to 7 days following admission. 
Results  Survival benefit from the use of intravenous insulin infusions was seen only for ST elevation 
infarctions not known to have diabetes; adjusted hazard ratio (HR) 0.77 (95% confidence interval 0.64 
- 0.92), p=0.005.   ST elevation infarctions with existing type 2 diabetes who received intravenous 
infusions had similar outcomes to routine care, HR 0.99 (95% CI 0.80 - 1.23), p=0.931.  For non-ST 
elevation infarctions routine care was associated with significantly better adjusted 7 day survival than 
intravenous infusions regardless of diabetes status; for those without known diabetes, HR 1.50 (95% 
CI 1.04 - 2.16)  p=0.029, and for those with type 2 diabetes, HR 1.35 (95% CI 1.08 - 1.70), p=0.010. 
Conclusion   In contemporary clinical practice, the use of intravenous insulin infusions to treat 
hyperglycaemia in acute coronary syndromes is associated with significant survival benefit only for 
those with ST segment elevation infarctions who are not known to have diabetes.  Non-ST segment 
elevation infarctions show significant survival benefit from routine care compared with intravenous 




In acute coronary syndrome (ACS), higher levels of blood glucose at admission are associated 
with lower survival rates,1-3 while early falls in those presenting with raised blood glucose are 
associated with improved survival.4   Normalization of glucose after admission is associated 
with better survival in hyperglycaemic patients with ACS whether or not they are treated with 
insulin.5   However, randomised studies that have examined the impact on mortality of lowering 
blood glucose with intravenous insulin infusions (IVII) have presented conflicting results.6-8  
The evidence for benefit rests on a single randomised study that did not achieve its primary end 
point,6  while other randomised studies using IVII have failed to show survival benefit.7,8 
 
Despite the limited evidence base, national clinical guidelines currently recommend IVII for ACS 
presenting with hyperglycaemia.9-13   However, there is presently no evidence that survival benefit 
from use of IVII applies across the spectrum of ACS, nor that responses of those with or without a 
prior diagnosis of diabetes are similar. The current limited use of insulin in ACS with hyperglycaemia 
reflects the weakness of the evidence base14. 
 
We used data from the National Audit of Myocardial Ischaemia Project (MINAP) database15 to 
examine the effect of IVII in patients with ACS presenting with glucose >=200 mg/dl. in the context 
of contemporary clinical practice.  We separately examined survival benefit from the use of IVII 
compared to routine care for those not known to have diabetes and for those with type 2 diabetes, and 
also for myocardial infarction presenting with ST segment elevation (STEMI) and without ST 
segment elevation (nSTEMI).  In order to assess the immediate effect of IVII, and to avoid any effect 
of intense post-discharge glycaemic control, we examined survival to seven days following 





The MINAP database contains details of ACS admissions to hospitals in England and Wales.15   The 
database records information on patient co-morbidity and management for both STEMI and nSTEMI, 
and for the purposes of this study provided information on admission blood glucose, type of diabetes, 
and pre-hospital and inpatient management of hyperglycaemia. Fully anonymised data were extracted 
from the MINAP database, and included records from all hospitals in England and Wales (n=220) 
accepting emergency admissions between January 2008 and March 2012. The United Kingdom Office 
of National Statistics provided mortality status.   
 
Patient cohort.   We examined management and outcomes for first admissions having a final 
diagnosis of troponin positive ACS, either with or without ST segment elevation, and who had an 
admission blood glucose within the range 200-900 mg/dl. (for mmol/l  multiply by 0.055).  ACS were 
categorised as STEMI and nSTEMI based on biomarker and electrocardiographic criteria.  Patients 
had either pre-existing type 2 diabetes treated with dietary restriction, or oral medication, with or 
without additional subcutaneous insulin, or were not known to have diabetes at the time of admission.  
Treatment allocation to IVII or routine care was determined by the attending physician.  Insulin 
infusions were prescribed according to local practice, and were not standardised. Blood glucose was 
measured either by bedside analysis or in the laboratory.   
 
Statistical analysis   We examined distributions of baseline variables of patient characteristics, 
cardiovascular risk factors, and glucose level and medications at hospital admission between 
patients receiving routine care and IVII.  Categorical variables were summarised using frequencies 
and percentages, and a χ2 test was used to compare differences between two groups. We used the 
median and interquartile range (IQR) for continuous variables, with the Mann-Whitney test for 
differences.  As preliminary analyses demonstrated significant differences in clinical characteristics 
between those receiving IVII and those receiving routine care, a multivariate logistic regression model 
was developed, based on important clinical features or having statistical significance on univariate 
analysis (p<0.001), to calculate the probability of being treated with IVII using the following 
variables: age, gender, admission blood glucose as a categorical variable, (200-217, >217-253, >253 – 
290, >290 – 326, >326 – 362, >362 – 900 mg/dl.), type of infarction (nSTEMI/STEMI), a previous 
history of myocardial infarction, hypertension, hyperlipidaemia, chronic renal failure (creatinine >200 
micromol/l), chronic obstructive airways disease, peripheral vascular disease, diabetes status, 
prescription of a loop diuretic (as a surrogate for development of heart failure during admission16), use 
of angiography,17 and  primary reperfusion strategy for STEMI (thrombolytic treatment, primary 
percutaneous coronary intervention (pPCI), or no reperfusion treatment).   We matched the propensity 
score to within 0.01 between patients having IVII and routine care using 1:1 matching criteria.  
Multivariate adjusted Cox regression models were then used to examine the effects of IVII on survival 
to 7 days after admission for those with STEMI and nSTEMI, and for patients with and without 
diabetes. The following covariates were also used in these models; treatment before admission with 
aspirin, angiotensin converting enzyme (ACE) inhibitors or receptor blockers, beta blockers, 
thienopyridines and statins, previous PCI, previous coronary artery bypass grafting, and current 
cigarette smoking.  In the adjustment analysis any missing data amongst the variables were coded and 
included in analysis. We tested for an interaction effect between IVII and routine care on 
mortality for STEMI and nSTEMI, and for those with diabetes and those not known to have 
diabetes, using a 2-sided p value, and calculated the ratio of hazard ratios for survival benefit 
with IVII.
18
  All analyses in this study were performed in the SAS statistical program (SAS 
Version 9.2, SAS Institute Inc, Cary, NC).  
 
Results 
From 36738 records of patients having an admission glucose in the range >= 200 mg/dl. to <=900 
mg/dl,  we identified 23506 patients who had either type 2 diabetes or were not known to have 
diabetes on admission to hospital, and who had an explicit management strategy for hyperglycaemia.  
70.3% (16520) received routine care and 29.7% (6986) had IVII.(figure 1)  Of 23506, 51.2% (12041) 
had type 2 diabetes and 48.8% (11465) were not known to have diabetes at admission; 43.5% 
(10216) had STEMI, and 56.5% (13290) nSTEMI. While IVII was used for 29.7% patients overall, it 
was used substantially more frequently for those with existing diabetes, 41.6% (5007 of 12041) than 
those not known to have diabetes, 17.1% (1979 of 11465).  
 
Table 1 shows patient characteristics for the whole cohort. Those having IVII and those having 
routine care differed in several important respects. Those receiving IVII were significantly younger, 
and were more likely to be male.  They also had a higher median admission glucose; 286 mg/dl 
against 235 mg/dl.  Those having STEMI were also more likely to receive insulin than those with 
nSTEMI.  Data on other clinical characteristics appear in on-line data table e1.   In view of the 
important differences between those having IVII and routine care, and the substantially greater use of 
IVII for those with known diabetes, we used matched propensity analysis to compare survival at 7 
days following admission.  Of 6986 patients having IVII 5974 (85.5%) were matched 1:1 with 
patients having routine care. The clinical characteristics of the matched cohort are shown in table 2. 
There were no significant differences in clinical characteristics, except that a higher proportion of 
patients with type 2 diabetes patients had routine care, and a higher proportion were using beta 
blockers before admission.   
 
Survival outcome at 7 days.  The 7 day mortality for all STEMI was 14.6%, (819 of 5608); for 
those with type 2 diabetes it was 11%, (338 of 3081) and for those not known to have diabetes 19%, 
(481 of 2527).  The 7 day mortality for nSTEMI was 7%, (444 of 6340); for those with type 2 
diabetes it was 6.1%, (311 of 5111), and for those not known to have diabetes it was 10.8%, (133 of 
1229).  For STEMI overall, IVII was associated with a 15% lower adjusted mortality compared with 
routine care; for patients without known diabetes there was a 23% lower mortality, while for those 
with known diabetes there was no significant difference.(table 3)  In contrast to STEMI, use of IVII 
for nSTEMI was associated with increased mortality, regardless of diabetes status.  After adjustment, 
the HR for 7 day survival favoured routine care over IVII; HR 1.42, p<0.001, for type 2 diabetes 
HR=1.35, p<0.001, and for those not known to have diabetes HR=1.5, p=0.029. An interaction 
analysis showed that the survival benefit effect of IVII was significantly more powerful for those 
with STEMI compared to nSTEMI; the ratio of hazard ratios (RRR) was 0.60 (0.47-0.76) overall, 
0.51 (0.34-0.77) in patients without known diabetes and 0.73 (0.54-1.01) in patients with known 
diabetes.  
 
The impact of primary reperfusion strategy on outcome for STEMI.  As mortality differed 
substantially between those having thrombolytic treatment (16.4%) , primary PCI (9.6%)  and those 
not having reperfusion treatment, (20.2%), the impact of IVII was examined for each group.  For 
those with established type 2 diabetes the HR for 7 day survival was similar for IVII and routine care 
in each reperfusion subgroup, in the range 0.89–1.09, p>0.05. (table 4).  For those not known to have 
diabetes, IVII was associated with marked survival benefit for those having thrombolytic treatment; 
HR 0.68, p=0.019 and for primary PCI; HR 0.71, p=0.047. In those not receiving reperfusion 
treatment, IVII did not show any survival benefit over routine care; HR 0.93, p=0.933.  
 
Sensitivity analyses   We performed a sensitivity analysis excluding those patients who had 
any missing data in any of the variables used for adjustment. The number of patients in the 
analysis was 8746, 73.2% of 11948 propensity matched patients.  There were no significant 
differences in those included between between IVII and routine care groups, and analyses 
showed similar overall results to those in tables 3 and 4.(tables e2 and e3).  However, the 
benefits of routine care on survival seen for nSTEMI were slightly attenuated, and were no 
longer significant in the subgroups of patients with and without diabetes.  A small proportion 
of those with diabetes (5.2%) received insulin with oral medication prior to admission.  We 
found that excluding this group from analysis also had no significant impact on the overall 
results. (table e4) 
 
Discussion  
This study using data from a national registry of ACS showed that, as used in contemporary clinical 
practice, survival benefit from the use of insulin infusions for hyperglycaemia did not extend to all 
ACS, but was limited to STEMI. This resulted from a 23% better adjusted survival outcome at seven 
days for STEMI without known diabetes, while for STEMI with known type 2 diabetes survival for 
those having IVII and routine care was the same.  For nSTEMI, routine care was associated with 
better outcome than IVII.  The difference in response to IVII between STEMI and nSTEMI was 
marked; an interaction analysis showed the survival benefit effect from IVII was significantly more 
powerful for those having STEMI than for nSTEMI.  
 
There is a strong patho-physiological basis for the toxicity of hyperglycaemia in ACS, based on 
oxidative stress,19,20  enhanced platelet activation and thrombin formation,21 and impaired response to 
antiplatelet drugs 22, which makes timely glucose control with insulin a plausible clinical approach.  
However, despite this, the evidence for survival benefit from the use of insulin to normalise raised 
blood glucose is based on a single randomised study that examined the combined effects of 
intravenous insulin in hospital and three months of intense post-discharge glycaemic control.6   
It remains uncertain to what extent the reported benefit at one year was due to intense 
glycaemic control after discharge, and how much was due to the in-hospital insulin.  Two other 
studies failed to show survival benefit for IVII.
7,8
 A recent randomised open label study using infarct 
size as an end point in a mixed population of STEMI (85%) and nSTEMI; type 2 diabetes (10 %), and 
those not known to have diabetes, failed to show a significant difference in infarct size between those 
randomised to intensive glycaemic control with insulin and those having routine care, despite those 
having insulin achieving significantly lower blood glucose values.23   Evidence for survival benefit 
from IVII is therefore limited to a small observational study from a cohort without prior diabetes 
presenting with a blood glucose >= 200 mg/dl.24   This showed findings consistent with the present 
study; a difference in effect of IVII between STEMI and nSTEMI, with survival benefit seen only for 
STEMI.    
In addition to the evidential limitations, the management of ACS has changed greatly since 
publication of DIGAMI 1 in 1995 and this may influence the present response to IVII.6   Primary PCI, 
accompanied by use of increasingly effective anti-platelet and anti-thrombotic medication is now the 
reperfusion treatment of choice for STEMI,25 while for nSTEMI angiography and, where appropriate, 
coronary intervention are now mandated.  Furthermore, the extensive use of angiotensin receptor 
inhibitors, and statins prior to admission may favourably influence early outcome independently of 
any intervention with insulin, by their effects on the no-reflow phenomenon.26, 27   These interventions 
may be sufficiently powerful to attenuate any effects of IVII, especially for nSTEMI where seven day 
mortality was one half of that seen for STEMI in this study. 
 
For STEMI in patients not known to have diabetes the effect of IVII was powerful, and was similar 
for those having thrombolytic treatment (HR 0.68 p = 0.019) and primary PCI (HR 0.71, p=0.047).  
However, in patients with STEMI who did not receive primary reperfusion treatment there was no 
survival benefit of IVII over routine care.  This heterogeneous group includes those who do not 
receive reperfusion treatment because of co-morbidities, those who present late, and those who are 
found to be unsuitable for, or did not require, an immediate intervention.  They represented 27% of all 
STEMI in this study, and it is possible that subsets within this group may yet benefit from IVII.  For 
STEMI in patients with type 2 diabetes, IVII was associated with similar outcomes to routine care, 
although the confidence limits did not exclude the possibility of a small benefit.  While the routine use 
of IVII would not appear justified for this group, these findings should not inhibit the use of IVII at 
higher levels of admission glucose and where hyperglycaemia may be associated with more general 
metabolic disturbance. 
 
For nSTEMI, whether or not patients had a prior diagnosis of type 2 diabetes, these analyses favoured 
routine care. These findings are similar, though more marked, to those in the DIGAMI 2 study7, 
where routine care for type 2 diabetes showed an early trend towards lower mortality when compared 
to IVII.   The potentially adverse effects of hypoglycaemia may be relevant.28-30  The use of insulin 
infusions for severely ill patients in the ITU setting, although not necessarily applicable to acute 
coronary ischaemia, initially suggested a target glucose range of 80-110 mg/dl,31  until concern about 
the adverse effects of hypoglycaemia on mortality encouraged a relaxation of this target.32  However, 
if an intensive glucose target was adopted by clinicians using DIGAMI regime, where hypoglycaemia 
rates of 15% were reported,6 this may have led to adverse outcomes, although more recent work, in 
the context of a clinical trial, has reported that lower rates of hypoglycaemia can be achieved while 
using a target range of 80-110 mg/dl.23 
 
These analyses confirm that those having type 2 diabetes, of whom the majority were taking oral 
medication, had a lower mortality than those not known to have diabetes.  While the mechanism 
whereby oral hypoglycaemic drugs favourably affect outcome may simply be by providing timely 
glycaemic control during the critical early phase of infarction, metformin, the recommended first-line 
oral medication in American, European,33 and United Kingdom guidelines,34 has additional beneficial 
metabolic effects.35   In patients with type 2 diabetes undergoing primary PCI for STEMI, pre-
admission use of metformin was associated with a lower frequency of the no-reflow phenomenon.36  
For those with type 2 diabetes the present findings support the continued use of oral therapy, 
particularly metformin, during the acute phase of infarction, and are consistent with the wider 
beneficial cardiovascular effects demonstrated for metformin by the UKPDS collaborators.37 
 
Despite having a lower mortality than those without known diabetes, those with known diabetes were 
more likely to receive IVII in this study.  Use of IVII was greater in those with type 2 diabetes and 
STEMI, 54%,  a group where we were unable to show survival benefit, than for STEMI without a 
prior diagnosis of diabetes where IVII were used for only 22%.  Even more limited use of intravenous 
insulin has recently been reported from the United States.14   This may reflect awareness amongst 
clinicians of the paucity of the evidence base, and continuing concerns about the potential adverse 
effects of IVII.  Scepticism for the role of IVII by clinicians appears to be justified on the basis of the 
present findings.   
 
Limitations. This large database inevitably had missing data. After excluding patients who had 
missing data in any of the variables used for adjustment, we found that the effects of IVII were 
broadly similar when compared to analyses that included all matched patients, although for nSTEMI 
the survival benefit of routine care for subsets with and without prior diabetes was slightly attenuated 
and no longer statistically significant. (tables e2, e3 on-line data).  In addition, the timing of the 
insulin infusion in relation to the onset of symptoms, which may be very important, was not routinely 
recorded.  However, from 2010 onwards this was recorded in the MINAP database in a group of 
patients with hyperglycaemia having ACS (n= 776) in 40 hospitals as part of the evaluation of a new 
intravenous insulin regime and provides an indication of contemporary practice (MINAP data on file); 
the median delay from arrival in hospital to insulin infusion was 4.3 h (IQR 2.6 - 7.7 h).  We also 
considered the risk of survivor bias from deaths occurring very early after admission, before insulin 
treatment could be started.  However, in previous work we have shown that when deaths within 24 h. 
of admission were excluded, 7 and 30 day adjusted outcomes were only slightly attenuated.24.  Finally, 
we do not have a record of the frequency of hypoglycaemic episodes which may of relevance to 
mortality outcome for nSTEMI. 
Conclusion.  We have shown that responses to IVII are not consistent between STEMI and nSTEMI, 
and that responses to IVII by those known to have diabetes differ from those without known diabetes.  
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Figure 1.  Origin of cohort with acute coronary syndrome and admission glucose >=11 mmol/l 
from which matched propensity groups were derived.  






n= 16520  
Insulin infusion 
n= 6986  p value 
Patient characteristics     
Age y  a 74.0  (62.9, 82.1) 70 (59.7, 79) <0.001 
Male gender 10163/16491 (61.6) 4475/6980 (64.1) <0.001 
Admission glucose mg/dl  a,b 235 (212, 275) 286 (235, 349) <0.001 
nSTEMI 9886/13290 (74.4) 3404/13290 (25.6) <0.001 
STEMI 6634/10216 (64.9) 3582/10216 (35.1) <0.001 
Diabetes status    
Type 2 diabetes 7034/16520 (42.6) 5007/6986 (71.7) <0.001 
        Diet control 1316/7034 (18.7) 679/5007 (13.6) <0.001 
        Oral medication 5657/7034 (80.4) 3765/5007 (75.1) <0.001 
        Oral plus insulin 61/7034 (0.9) 563/5007 (11.2) <0.001 
Not known to have diabetes 9486/16520 (57.4) 1979/6986 (28.3) <0.001 
Table 1. Main clinical characteristics of the whole cohort, n= 23506.    a  median, interquartile range.  b For mmol/l  
multiply by 0.055. Bracketed numerals are percentages except where otherwise indicated.  Details of other  
previous medical history, drugs taken before admission, and hospital care, appear in the Appendix table e1. 
  
 Routine care 





 Age, y a    71.0 (59.9-80.0) 70.0(59.7-79.0) 0.928 
Male gender 3854/5970 (64.6) 3797/5969(64.6) 0.282 
Final diagnosis:  
       STEMI 2762 (47.6) 2846 (46.2) 0.124 
       NSTEMI 3212 (52.4) 3128 (53.8)  
Admission Glucose mg/dl a b 272 (230, 326) 272 (230, 326) 0.096 
Diabetes status    
   Not known diabetes 1826 (30.6) 1930 (32.3) 0.040 
   Type 2 diabetes  4148 (69.4)        4044 (67.7)  
Previous medical status     
  Hypertension 3483/5805 (60) 3438/5804 (59.2) 0.401 
  Hyperlipidaemia 2418/5679 (42.6) 2388/5682 (42.0) 0.553 
  Previous MI 1379/5803 (23.8) 1384/5799 (23.9) 0.897 
  Heart Failure 402/5780 (7.5) 399/5783 (6.9) 0.906 
  Chronic Renal Failure 401/5771 (6.9) 397/5775 (6.9) 0.246 
  Chronic obstructive pulmonary disease 844/5767 (14.6) 842/5775 (14.6) 0.933 
  Previous PCI 509/5795 (8.9) 521/5777 (9.0) 0.657 
  Previous CABG 382/5806 (6.6) 400/5791 (6.9) 0.481 
  Current cigarette smoking 1482/5560 (26.7) 1452/5595 (26) 0.399 
Medication taken before admission:    
    ACEI or ARB 2543/5580 (45.6) 2579/5650 (45.6) 0.999 
    Beta blocker 1787/5589 (32.0) 1698/5653 (30.0) 0.026 
    Statin 3004/5707 (52.6) 3014/5783 (51.9) 0.578 
    Aspirin 1568/5745 (27.3) 1647/5774 (28.5) 0.141 
   Thienopyridine 730/5306 (13.8) 725/5307 (13.7) 0.885 
Primary reperfusion for STEMI:    
    No primary reperfusion treatment 775/2762 (28.1) 787/2846 (27.7) 0.817 
    Thrombolytic treatment 796/2762 (28.8) 842/2846 (29.6)  
    Primary angioplasty 1191/2762 (43.1) 1217/2846 (42.8)  
    Angiography for nSTEMI 1852/2879 (64.3) 1817/2835 (64.1) 0.879 
    Use of loop diuretic 2357/5688 (41.4) 2379/5683 (41.9) 0.647 
 
Table2.  Clinical characteristics of propensity matched groups.  Bracketed numerals are percentages except where  













STEMI (all) Routine care 2762 451    (16.3) 1  
 Insulin infusion 2846 368    (12.9) 0.85  (0.74 - 0.98) 0.026 
With type 2 diabetes Routine care 1503 175    (11.6) 1  
 Insulin infusion 1578 163    (10.3) 0.99  (0.80 - 1.23) 0.931 
Not known to have diabetes Routine care 1259 276    (21.9) 1  
 Insulin infusion 1268 205    (16.2) 0.77   (0.64 - 0.92)  0.005 




186     (5.8) 
258     (8.2) 
1 
1.42  (1.17 - 1.72) 
 
<0.001 
  With type 2 diabetes Routine care 2645 133     (5.0) 1  
 Insulin infusion 2466 178     (7.2) 1.35  (1.08 - 1.70) 0.010 
 Not known to have diabetes Routine care  567 53       (9.3) 1  
 Insulin infusion  662 80     (12.1) 1.50  (1.04 - 2.16) 0.029 
















Type 2 diabetes Thrombolytic treatment Routine care 305 44    (14.4) 1  
 Insulin infusion 398 44    (11.1) 0.89  (0.55 - 1.42) 0.612 
Primary angioplasty Routine care 684 45      (6.6) 1  
 Insulin infusion 714 41      (5.7) 0.90  (0.57 - 1.43) 0.668 
No primary reperfusion Routine care 514 86    (16.7) 1  
 Insulin infusion 466 78    (16.7) 1.09  (0.79 - 1.49) 0.614 
       
Not known to 
have diabetes 
Thrombolytic treatment Routine care 491 114   (23.2) 1  
 Insulin infusion 444 67    (15.1) 0.68  (0.49 - 0.94) 0.019 
Primary angioplasty Routine care 507 87    (17.2) 1  
 Insulin infusion 503 62    (12.5) 0.71  (0.50 - 0.99) 0.047 
No primary reperfusion Routine care 261 75    (28.7) 1  
 Insulin infusion 321 76    (23.7) 0.93  (0.66 - 1.31) 0.933 
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 Previous medical status 
Routine care 
n= 16520 (%) 
Insulin infusion 
n= 6986   (%)           
p 
value 
     
Hypertension 8978/16120  (55.7) 4041/6773 (59.7) <0.001 
Cardiac failure 1181/16034  (7.4) 472/6744   (7) 0.33 
Chronic obstructive airways disease 2598/16046  (16.1) 959/6732   (14.2) <0.001 
Chronic renal failure 1022/16052  (6.4) 457/6739   (6.8) 0.246 
Treated hyperlipidaemia 5538/15815  (35) 2860/6615 (43.2) <0.001 
Myocardial infarction 3891/16090  (24.2) 1595/6771 (23.6) 0.311 
Peripheral vascular disease 727/15844    (4.6) 383/6582   (5.8) <0.001 
CABG 1035/16107  (6.4) 458/6719   (6.8) 0.341 
PCI 1307/16075 (8.1) 616/674     (39.1) 0.013 
Current cigarette smoking 3856/15335 (25.1) 4475/6980 (26.9) 0.008 
Admission drugs      
ACEI/ARB 6411/15459 (41.5) 3020/6599 (45.8) <0.001 
Aspirin 4259/15835 (26.9) 1897/6746 (28.1) 0.059 
beta blocker 4695/15835 (30.3) 1961/6605 (29.7) 0.356 

























thienopyridine 1872/14722 (12.9) 835/6180  (13.5) 0.196 
In hospital management      
  Primary angioplasty 3162/6634  (47.7) 1457/3582  (40.7) <0.001 
  Thrombolytic treatment 1511/6634  (22.8) 1157/3582  (32.3) <0.001 
  No reperfusion 1961/6634  (29.6) 968/3582    (27) <0.001 
  Angiography for nSTEMI 5069/8834  (57.4) 2051/3141  (65.3) <0.001 



































STEMI (all) Routine care 259/1942 13.3 1.00  
 Insulin infusion 221/2030 10.9 0.79 (0.66-0.95) 0.012 
 With type 2 diabetes Routine care 104/1058 9.8 1.00  
 Insulin infusion 100/1136 8.8 0.90 (0.68-1.19) 0.466 
 Not known to have diabetes Routine care 155/884 17.5 1.00  
 Insulin infusion 121/894 13.5 0.70 (0.55-0.89) 0.004 
      
nSTEMI (all) Routine care 127/2424 5.2 1.00  
 Insulin infusion 157/2350 5.7 1.31 (1.03-1.66) 0.026 
  With type 2 diabetes Routine care 90/2017 4.5 1.00  
 Insulin infusion 103/1853 5.6 1.29 (0.97-1.71) 0.085 
  Not known to have diabetes Routine care 37/407 9.1 1.00  
 Insulin infusion 54/497 10.7 1.27 (0.83-1.96) 0.275 
 Table e2  Sensitivity analysis. Patients without any missing covariate data.  Hazard ratio for 7 day survival for STEMI and nSTEMI.  










7 days (%) 
Adjusted HR p 
Type 2 
diabetes 
Thrombolytic treatment Routine care 24/215 11.2 1.00  
 Insulin infusion 29/294 9.9 0.94 (0.52-1.68) 0.833 
Primary angioplasty Routine care 24/477 5.0 1.00  
 Insulin infusion 25/509 4.9 0.85 (0.47-1.52) 0.575 
No primary reperfusion Routine care 56/366 15.3 1.00  
 Insulin infusion 46/333 13.8 0.92 (0.61-1.38) 0.896 
       
Not known to 
have 
diabetes 
Thrombolytic treatment Routine care 60/335 17.9 1.00  
 Insulin infusion 35/307 11.4 0.57 (0.37-0.88) 0.011 
Primary angioplasty Routine care 54/366 14.8 1.00  
 Insulin infusion 39/367 10.6 0.61 (0.40-0.94) 0.026 
No primary reperfusion Routine care 41/183 22.4 1.00  
 Insulin infusion 47/220 21.4 1.03 (0.67-1.61) 0.883 
Table e3  Sensitivity analysis.  Patients without any missing covariate data. Hazard ratio for 7 day survival for individual primary  




















STEMI (all) Routine care 488/2745 16.3 1.00  
 Insulin infusion 361/2713 13.3 0.87 (0.75 – 0.99) 0.048 
STEMI with type 2 diabetes  Routine care 172/1486 11.6 1.00  
 Insulin infusion 156/1445 10.8 1.04 (0.83 – 1.30) 0.751 
nSTEMI (all) Routine care 183/192 5.8 1.00  
 Insulin infusion 243/2810 8.6 1.44 (1.19 – 1.75) <0.001 
nSTEMI with type 2 diabetes Routine care 132/2625 5.0 1.00  
 Insulin infusion 163/2148 7.6 1.37 (1.09 – 1.74) 0.008 
Table e4.  Sensitivity analysis after exclusion of patients with type 2 diabetes (n=624) using subcutaneous insulin with oral 
 Medications before admission.   Routine care = 1. 
 
 
